Valuation: Incyte Corporation

Market Cap 2.59TCr 2.22TCr 2.07TCr 1.9TCr 3.57TCr 2,48000Cr 3.61TCr 25TCr 9.55TCr 1,24400Cr 9.73TCr 9.51TCr 4,11800Cr P/E 2026 *
57x
P/E 2027 * 17.7x
Enterprise Value 2.17TCr 1.86TCr 1.74TCr 1.59TCr 2.98TCr 2,07500Cr 3.02TCr 21TCr 7.99TCr 1,04100Cr 8.14TCr 7.96TCr 3,44500Cr EV / Sales 2026 *
3.65x
EV / Sales 2027 * 3.18x
Free-Float
98.15%
Yield 2026 *
-
Yield 2027 * -
1 day+0.46%
1 week+6.37%
Current month+6.94%
1 month+10.38%
3 months+31.55%
6 months+26.14%
Current year+29.40%
1 week 119.64
Extreme 119.64
129.92
1 month 115.77
Extreme 115.77
132.6
Current year 89.25
Extreme 89.25
132.6
1 year 81.09
Extreme 81.09
132.6
3 years 50.27
Extreme 50.27
132.6
5 years 50.27
Extreme 50.27
132.6
10 years 50.27
Extreme 50.27
153.15
Manager TitleAgeSince
Chief Executive Officer 58 26/06/2025
Director of Finance/CFO 57 04/05/2026
President 62 05/06/2023
Director TitleAgeSince
Chairman 59 26/06/2025
Director/Board Member 72 20/01/2015
Director/Board Member 64 20/01/2015
Date Insider Type Main position Quantity % Market Cap.
19/08/26 Sell

Chairperson

-10,801 0.0053%
12/08/26 Sell

Chairperson

-10,803 0.0053%
05/08/26 Fiscal year

EVP & Chief Scientific Officer

6,621 0.0033%
Change 5-day change 1-year change 3-year change Capi.($)
+0.46%+6.37%+50.29%+97.27% 2.59TCr
+0.90%+3.80%+41.49%-0.78% 8.33TCr
+8.86%+129.20%+435.14%+24.85% 5.79TCr
-1.69%+23.30%-25.53%-36.93% 5.78TCr
-1.46%+0.19%-0.81%+29.66% 5.17TCr
+1.74%+4.43%+12.37%+169.64% 4.93TCr
+1.13%+3.31%+55.61%-17.57% 3.2TCr
+1.19%+9.17%+3.12%+228.73% 2.27TCr
-0.30%+4.45%+60.84%+124.17% 1.69TCr
-5.74%+1.91%+2.59%+825.47% 1.61TCr
Average +0.51%+18.61%+63.51%+144.45% 4.14TCr
Weighted average by Cap. +1.16%+24.07%+77.29%+76.56%

Financials

2026 *2027 *
Net sales 594.19Cr 508.82Cr 475.85Cr 435.62Cr 817.85Cr 57TCr 828.84Cr 5.62TCr 2.19TCr 29TCr 2.23TCr 2.18TCr 94TCr 626.5Cr 536.48Cr 501.73Cr 459.31Cr 862.32Cr 60TCr 873.9Cr 5.93TCr 2.31TCr 30TCr 2.35TCr 2.3TCr 1LCr
Net income 47Cr 40Cr 37Cr 34Cr 64Cr 4.46TCr 65Cr 440.78Cr 171.8Cr 2.24TCr 174.89Cr 171.07Cr 7.4TCr 149.59Cr 128.09Cr 119.79Cr 109.67Cr 205.89Cr 14TCr 208.66Cr 1.42TCr 551.67Cr 7.18TCr 561.59Cr 549.34Cr 24TCr
Net Debt -422.97Cr -362.19Cr -338.73Cr -310.09Cr -582.17Cr -40TCr -590Cr -4TCr -1.56TCr -20TCr -1.59TCr -1.55TCr -67TCr -599.09Cr -513.01Cr -479.77Cr -439.21Cr -824.59Cr -57TCr -835.67Cr -5.67TCr -2.21TCr -29TCr -2.25TCr -2.2TCr -95TCr
Logo Incyte Corporation
Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).
Employees
2,844
Date Price Change Volume
21/26/21 $127.81 +0.46% 13,67,411
20/26/20 $127.22 -0.97% 12,07,144
19/26/19 $128.47 +4.05% 15,89,005
18/26/18 $123.47 -0.02% 11,91,480
17/26/17 $123.50 +2.78% 20,40,676
Trader
Investor
Global
Quality
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
28
Last Close Price
127.81USD
Average target price
127.12USD
Spread / Average Target
-0.54%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INCY Stock